Despite these protective effects, LXR agonist administration induces hepatic lipogenesis and elevates triglyceride levels, leading to steatosis in mice,549 an effect driven by LXRα-mediated upregulation of SREBP-1c and FASN expression.44 This evidence concerns the gene SREBF1 and steatosis.